Last $0.07 USD
Change Today -0.003 / -4.00%
Volume 1.2M
ISCO On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Open
$0.08
Previous Close
$0.08
Day High
$0.08
Day Low
$0.07
52 Week High
01/9/14 - $0.28
52 Week Low
07/9/14 - $0.06
Market Cap
16.1M
Average Volume 10 Days
1.2M
EPS TTM
$-0.07
Shares Outstanding
224.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERNATIONAL STEM CELL CORP (ISCO)

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 11/25/14
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $258.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $182.0K
Compensation as of Fiscal Year 2013.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Approves Certificate of Amendment to its Certificate of Incorporation

International Stem Cell Corporation announced that the special meeting held on December 4, 2014, approved the Certificate of Amendment to its Certificate of Incorporation to increase the aggregate number of shares of common stock which the Company will have authority to issue from 600,000,000 shares to 720,000,000 shares.

International Stem Cell Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

International Stem Cell Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1,963,000 compared to $1,670,000 a year ago. Loss from operating activities was $2,034 compared to $1,703 a year ago. Loss before income taxes was $2,034 compared to $3,799 a year ago. Net loss applicable to common stockholders was $2,034,000 or $0.01 per basic and diluted share compared to $3,799,000 or $0.03 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $5,200,000 compared to $4,412,000 a year ago. Loss from operating activities was $6,342 compared to $5,609 a year ago. Loss before income taxes was $7,879 compared to $7,712 a year ago. Net loss applicable to common stockholders was $7,879,000 or $0.04 per basic and diluted share compared to $7,712,000 or $0.07 per basic and diluted share a year ago. Net cash used in operating activities was $4.45 million for the nine months ended September 30, 2014, compared to $4.23 million for the corresponding period in 2013. The company invested $746,000 in capital and patent expenditures year-to-date in 2014.

International Stem Cell Corporation, Q3 2014 Earnings Call, Nov 14, 2014

International Stem Cell Corporation, Q3 2014 Earnings Call, Nov 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.07 USD -0.003

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.01 USD -0.0008
Cytori Therapeutics Inc $0.51 USD -0.0061
Nuo Therapeutics Inc $0.36 USD +0.043
StemCells Inc $0.96 USD -0.0287
Vericel Corp $2.87 USD -0.01
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit www.internationalstemcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.